Vir Biotechnology, Inc. Form 4 (Dec. 15, 2021)

Summary

In this Form 4, Phillip Pang, Chief Medical Officer of Vir Biotechnology, Inc. [VIR], reports an option exercise and sales of common stock on 12/15/2021. The reporting person acquired 5,000 shares by exercising an option at $1.53, then sold 1,716 shares at a weighted average price of $49.4142, 1,050 at $50.603, 1,034 at $51.2957 and 1,200 at $52.2004, ending with 92,777 shares owned directly. Table II shows 72,591 options left after the exercise, and a footnote states that 1/4 of the option shares vested on April 27, 2019 with the rest vesting in 36 equal monthly installments. The sales were made under a Rule 10b5-1 trading plan adopted on February 19, 2021. Howard Horn signs as Attorney-in-Fact on 12/16/2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Pang Phillip (Last) (First) (Middle) C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 (Street) SAN FRANCISCO CA 94158 (City) (State) (Zip) | Pang Phillip | (Last) | (First) | (Middle) | C/O VIR BIOTECHNOLOGY, INC. | 499 ILLINOIS STREET, SUITE 500 | SAN FRANCISCO | CA | 94158 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Vir Biotechnology, Inc. [ VIR ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Medical Officer | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | Chief Medical Officer
3. Date of Earliest Transaction
 (Month/Day/Year) 12/15/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 12/15/2021 | M | 5,000 | A | $ 1.53 | 97,777 | D
Common Stock | 12/15/2021 | S (1) | 1,716 | D | $ 49.4142 (2) | 96,061 | D
Common Stock | 12/15/2021 | S (1) | 1,050 | D | $ 50.603 (3) | 95,011 | D
Common Stock | 12/15/2021 | S (1) | 1,034 | D | $ 51.2957 (4) | 93,977 | D
Common Stock | 12/15/2021 | S (1) | 1,200 | D | $ 52.2004 (5) | 92,777 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Stock Option (Right to Buy) | $ 1.53 | 12/15/2021 | M | 5,000 | (6) | 04/27/2018 | Common Stock | 5,000 | $ 0.00 | 72,591 | D
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.91 to $49.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.9825 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.95 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.01 to $52.59 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.
Remarks:
/s/ Howard Horn, Attorney-in-Fact | 12/16/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_VIR_4_filed2021-12-17_0001209191-21-070325.xml

Size

21,277 bytes

SHA-256

298a0d9c52ef0e37301e2c7b5afebde30a6efda86c0a77672b76a941a9afd855

Our copy

SEC_VIR_4_filed2021-12-17_0001209191-21-070325.xml

Original

www.sec.gov